<DOC>
	<DOC>NCT02041091</DOC>
	<brief_summary>The purpose of this study is to evaluate the amount of tabalumab in the blood after it is given by two different injection methods - A traditional syringe or a spring loaded syringe for 12 weeks. Participants may continue to receive study drug for up to 52 weeks.</brief_summary>
	<brief_title>A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Diagnosis of Lupus. Able and willing to have blood drawn for PK sampling. Have severe active lupus nephritis. Have severe active central nervous system (CNS) or peripheral neurologic disease or other severe neurologic involvement requiring treatment within approximately 3 months prior to screening. Have received high dose corticosteroid within approximately 1 month prior to baseline. Have initiated or adjusted treatment with immunosuppressant drugs within approximately 1 month prior to baseline. Have received plasmapheresis within approximately 3 months prior to baseline. Have previously received approved or experimental B cell targeted therapies within the last year. Have received any biologic or nonbiologic therapy within approximately 3 months or 5 halflives (whichever is longer). Have a history of severe reaction to any biologic therapy. Have an active or recent infection within approximately 1 month prior to Week 0. Have had a serious infection within approximately 3 month or serious bone/joint infection within approximately 6 months prior to baseline. Have evidence of or test positive for active hepatitis B or are positive for hepatitis C or human immunodeficiency virus (HIV). Have evidence of active or latent tuberculosis. Have significant hematological abnormalities.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>